Kainate Receptor Antagonists: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Jason Zhu and Version 1 by Ewa Szymanska.

Since the 1990s, ionotropic glutamate receptors have served as an outstanding target for drug discovery research aimed at the discovery of new neurotherapeutic agents. With the recent approval of perampanel, the first marketed non-competitive antagonist of AMPA receptors, particular interest has been directed toward ‘non-NMDA’ (AMPA and kainate) receptor inhibitors. Although the role of AMPA receptors in the development of neurological or psychiatric disorders has been well recognized and characterized, progress in understanding the function of kainate receptors (KARs) has been hampered, mainly due to the lack of specific and selective pharmacological tools. The latest findings in the biology of KA receptors indicate that they are involved in neurophysiological activity and play an important role in both health and disease, including conditions such as anxiety, schizophrenia, epilepsy, neuropathic pain, and migraine. 

  • glutamate ionotropic receptors
  • kainate receptors
  • antagonist

1. Competitive Antagonists of the Kainate Receptors

1.1. Quinoxaline-2,3-diones

Quinoxaline-2,3-dione analogues are one of the most intensively studied classes of competitive AMPAR/KAR antagonists. The early generation of quinoxalinediones, such as CNQX (1, Figure 1), DNQX (2), or NBQX (3), was reported in the 1980s and 1990s as potent AMPAR/KAR antagonists and neuroprotective agents [68,69,70,71,72][1][2][3][4][5]. Many members of this class also showed effects at the glutamate and, particularly, the glycine (GlyN) binding sites of the NMDA receptor. Among them, NBQX was the first compound to exhibit a high selectivity for AMPAR versus NMDAR and has been used as the referential antagonist of choice in numerous in vitro and in vivo models. The neuroprotective, anticonvulsant, anxiolytic, and antinociceptive effects of NBQX have been widely investigated and reported [69,73,74,75,76,77,78,79,80,81][2][6][7][8][9][10][11][12][13][14]. Neuroprotective properties of NBQX in ischemic stroke were confirmed in clinical studies; however, due to the low aqueous solubility and associated nephrotoxicity at therapeutic doses, it was rejected in the second phase of clinical studies [82][15].
Ijms 24 01908 g003 550
Figure 1. Structures of selected KAR antagonists based on the quinoxaline-2,3-dione structure.
The subsequent years progressed with numerous studies aimed at improving the affinity and selectivity toward AMPA receptors, the results of which have been reviewed in detail by Nikam [83][16], Catarzi [82][15], and Larsen [84][17]. Among them, particularly notable are YM90K (4), YM872 (5), and ZK200775 (6), active and selective AMPA receptor antagonists, also showing a micromolar binding affinity at the native kainate receptors [85,86,87,88][18][19][20][21]. Relevant structural modifications improved the affinity of the compounds of the AMPAR and solved the problem of low water solubility. Both YM872 and ZK200775 have demonstrated neuroprotective activity in animal models of acute and ischemic stroke and have become the subject of clinical trials [85,86,87,88][18][19][20][21]. Furthermore, YM872 showed neuroprotective properties in brain hemorrhage, as well as therapeutic potential in malignant primary glioma [89,90][22][23].
Selectivity toward KA receptors over AMPA receptors has been shown for pyrrolylquinoxaline-2,3-dione analogues, including the highly potent LU97175 (7, Figure 1), the compound substituted with a benzhydrazide group at the N1 position of the quinoxalinedione core [72][5]. Interestingly, LU97175 was reported to preferentially bind to the GluK3 homomeric receptors compared not only to the AMPA subtype GluA2, but also to the other individual kainate subtypes GluK1, GluK2, and GluK5 [72,92][5][24]. In an in vivo kindling model of temporal lobe epilepsy, LU97175 displayed anticonvulsant activity without inducing motor damage [71,72,93][4][5][25].
Among the examples of highly selective antagonists for homomeric GluK1 receptors are pyrrolyl quinoxalinediones BSF 91594 (8), BSF 111886 (9), and BSF 84077 (10), possessing an aliphatic amine (e.g., piperazine) linker attached to the pyrrole ring (Figure 1). Compounds 8 and 9 were found to be potent GluK1 ligands with more than a 100-fold selectivity over other kainate subtypes (Table 2). All three compounds showed a moderate to weak affinity at the native AMPA receptors and weak or no binding to the NMDA glycine binding site. When tested in vivo, 8, 9, and 10 confirmed their anticonvulsant potency in NMDA-induced seizures with effective median doses of 14, 21, and 3.3 mg/kg, respectively [94][26].
The LU97175 structure became the starting point for further modifications of the quinoxalinedione scaffold at positions N1, 6, and 7. SAR studies for the recently reported series of N1-substituted analogues confirmed that, also for compounds without a pyrrole ring in position 7 (and possessing a fluorine or nitro group instead), the N1-benzamide moiety was optimal for binding to the GluK1-3 recombinant receptors (11–14) and sufficient to achieve an affinity profile similar to LU97175 (12), while compounds with smaller or non-aromatic substituents in position N1 showed a significantly lower KAR affinity [92][24]. Attempts to bioisosterically replace the pyrrolyl moiety in the structure of LU97175 resulted in another series of derivatives, among which a 7-imidazole analogue (15) exhibited the highest binding affinity across the recombinant receptors GluK1-3 and the 73-fold binding selectivity for GluK3 over the AMPA subtype GluA2 [95][27]. In a mouse tail flick test for acute pain, 15 was shown to have an analgesic effect and was more effective than NBQX, suggesting that, contrary to an earlier hypothesis [75][8], the analgesic effects observed for early generation quinoxalinediones could also be mediated by kainate receptors. Furthermore, 15 did not show an adverse effect on motor coordination in the rotarod test as previously observed for NBQX, and it was found to cause an increase in locomotor activity [95][27].
The binding mode of 15 in the GluK1 binding pocket was determined by X-ray crystallography, showing a strong analogy to other complexes of quinoxaline-2,3-diones cocrystallized with the LBDs of non-NMDA receptors. Among others, 15 forms hydrogen bonds between the carbonyl groups of the quinoxalinedione core and Arg523 of domain 1, the residue considered crucial for the binding of l-glutamate, agonists, and competitive antagonists, and conserved within all AMPA and KA subunits [11,96][28][29]. The quinoxaline-2,3-dione core is also involved in H-bond contacts with other residues important for ligand binding: Thr518 and Pro516, while the position of the molecule is stabilized by π−π stacking between the quinoxaline-2,3-dione system and Tyr489 [95][27]. Despite the fact that 15 does not form any direct hydrogen bond with the residues of domain 2, the ligand, similarly to other quinoxalinediones, induces the opening of the LBD consistent with an antagonist binding mode. Analysis of the 15-GluK1-LBD X-ray structure also revealed the presence of a sulfate ion in the ligand-binding site. Considering that the unsubstituted imidazole nitrogen atom of 15 is probably protonated (the complex was crystallized at pH 4.5), it likely forms a salt bridge with a sulfate ion, which could explain the higher activity of this compound compared to LU97175 [95][27].
The N1-benzamide analogue 16 with an unsubstituted 7-position of the quinoxalinedione scaffold and possessing a phenylethynyl moiety at position 6 (Figure 1), demonstrated an interesting selectivity profile showing approximately a 30-fold preference for the GluK3 homomeric receptors over the subtypes GluK1 and GluK2 [92][24]. Following 16 as the lead structure, a series of quinoxaline-2,3-dione analogues with an ethynyl substituent at the 6-position has recently been presented [97][30]. The introduction to this position of a large bicyclic substituent linked by a triple bond to the quinoxalinedione core (17, 18) appeared to be an important structural modification that clearly affected the binding to the GluK3 subunit, resulting in the compound 17 with a pronounced preference for GluK3 and submicromolar GluK3 affinity. In fact, a 400-fold selectivity for GluK3 over the subtypes GluK1, GluK2, GluK5, and GluA2, reported for this analogue, has been a unique KA receptor affinity profile among all structures described to date [97][30]. On the other hand, the most active compound in this series, 18, showed a weak selectivity profile but a high affinity at the homomeric receptors GluK1, GluK3, and also GluK2, thus presenting one of the highest GluK2-affinity values among the quinoxalinedione-based ligands reported so far.
Demmer et al. presented a different approach to the design of quinoxalinedione structures [98,101][31][32]. The proposed modification focused on the combination of an unsubstituted quinoxaline-2,3-dione core with an amino acid chain (19) [98][31] or an acid moiety, varied in chemical functionalities, carbon chain length, and flexibility (20) [101][32]. The amino acid derivative CNG-10300 (19) exhibited a weak micromolar affinity for homomeric GluK1-3 receptors with Ki values of 16, 9.5, and 59 μM, respectively, and was successfully cocrystallized with the GluK1-LBD. Analysis of this X-ray complex indicated that the amino acid moiety of 19 did not interact with the protein in the way observed for typical α-amino acid agonists but was involved in interactions that stabilized an open antagonist state of the binding pocket [98][31]. Micromolar binding to GluK1-3 was also observed among the series of compounds containing an acidic group. The most active kainate ligand, 20, with an affinity of 1.2 µM for the GluK1 homomeric receptors showed more than a 27-fold selectivity over the kainate subtypes GluK2 and GluK3, and a 20-fold selectivity over the native AMPA receptors [101][32]. In a broader sense, the weak KAR affinity of the described monosubstituted quinoxalinediones confirmed the need for an additional core substitution in N1 to achieve a high affinity for the kainate receptors.

1.2. α-Amino Acid Antagonists

1.2.1. Willardiines

A separate group of competitive AMPA/KAR antagonists includes compounds with α-amino acidic functionality, most often linked through a heterocyclic ring system with a distal acidic group; for example, a carboxylate or phosphonate, or their isostere, for example, tetrazolyl ring. Undoubtedly, the most important chemical class within this category is willardiine derivatives, developed based on the natural agonist of the AMPA/KA receptor, willardiine ((S)-1-(2-amino-2-carboxyethyl)pyrimidine-2,4-dione). One of the first attempts to achieve an antagonistic AMPAR/KAR profile among willardiine derivatives involved the introduction of a 4-carboxylbenzyl (UBP282, 21) or 2-carboxybenzyl (UBP296, 22) substituent at position N3 (Figure 2) [102,103][33][34]. Subsequent studies have shown that both UBP296 and its purified S-enantiomer UBP302 (23) proved to be potent and highly selective GluK1 antagonists, with a negligible binding affinity at the homomeric rat GluK2, GluK5, or GluK2/GluK5 heteromers. UBP296 was further characterized on the native GluK1-containing receptors in the hippocampal mossy fibers and was found to play a role in controlling synaptic transmission in the CA1 and CA3 regions and reversibly block LTP induction in MF synapses [103][34].
Ijms 24 01908 g004 550
Figure 2. Structures of selected willardiine-based KAR antagonists. * the stereoisomeric center in the molecule.
Later findings showed that the benzene moiety could be successfully replaced with the tiophene ring (UBP310, 24), resulting in a >500-fold selectivity for native KA receptors over AMPA and NMDA receptors expressed in neonatal rat motor neurons. Further studies on cloned homomeric KARs revealed a high selective affinity of 24 at the GluK1 and GluK3 receptors [104,105,106][35][36][37]. Interestingly, it was reported that, although glutamate-evoked currents mediated by recombinant GluK3 homomeric receptors were effectively blocked by UBP310 (with an IC50 of 4.0 μM), the compound did not block recombinant GluK2/3 heteromers and, unlike CNQX, it did not affect presynaptic kainate receptors in mouse hippocampal mossy fiber synapses, which are most likely composed of GluK2/3 heteromers. A similar behavior was observed for the compounds UBP302 (23) and ACET (UBP316, 25) [23][38]. In addition, UBP310 demonstrated activity toward postsynaptic GluK2/5 receptors, inhibited slow excitatory postsynaptic currents (EPSC) mediated by KARs in epileptic mice, and was successfully tested in a mouse model of temporal lobe epilepsy [44][39].
The neuroprotective potential of UBP310 was studied in animal models of Parkinson’s disease (PD) [107][40]. Administration of this compound significantly improved the survival of the dopaminergic and total neuronal population in the substantia nigra pars compacta (SNpc) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD. On the contrary, UBP310 lacked the ability to influence the MPTP-induced loss of dopamine levels or striatum dopamine transporter expression, and the deletion of GluK1, GluK2, or GluK3 appeared to have no effect on the MPTP- or UBP310-induced effects. Furthermore, 24 did not reduce the intracerebral cell loss induced by 6-OHDA intoxication. The results clearly suggested that the neuroprotective effects mediated by UBP310 in the midbrain were not related to its affinity for the specific kainate receptor subunits [107][40].
Recent studies have also revealed that UBP310, as an antagonist specific for the GluK1 subunit, was able to reduce the glutamate-induced desensitization of heteromeric GluK1/2 and GluK1/5 receptors. As the binding of an agonist by one subunit may be sufficient for receptor activation, but not sufficient for receptor desensitization, it is reasonable to believe that subunit-selective antagonists can be used as tools to efficiently reduce heteromeric receptor desensitization [108][41].
X-ray crystal structures solved for GluK1-LBD in complex with UBP302 and UBP310 have been used to design a close analogue of UBP310, ACET (UBP316, 25), with a similar pharmacological profile. The ACET compound was applied to revisit the physiological role of kainate receptors in the NMDAR-independent mossy fiber LTP, as well as to establish the presynaptic regulation of Ca2+ facilitation in giant mossy fiber boutons (MFB). As a potent antagonist of GluK1-containing KARs (Kb approximately 1 nM), 25 was found to fully block LTP induction in the CA3-MF region of the hippocampus in a reversible manner, as well as to depress the presynaptic short-term facilitation of calcium transients in the MFB evoked by a train of action potentials [23,109][38][42].
So far, the crystal structures of the GluK1-LBD in complex with willardiine derivatives have been resolved for 23, 24, and 25 [104,109][35][42], all revealing an analogous binding mode of the ligand with residues of the LBD domains 1 and 2. In all cases, the carboxylic group of amino acid functionality was involved in the essential ion pair interaction with the side chain of Arg508 (the numbering of residues in the rat GluK1-LBD construct according to ref. [104][35]), as well as a hydrogen bond with the backbone amide group of Thr503. The α-amino group formed H-bond contacts with Thr503 and Pro501. Furthermore, for all three willardiine derivatives, a direct hydrogen bond interaction was observed between the distal carboxyl group and the amide group of Thr675.

1.2. Decahydroisoquinolines

Decahydroisoquinoline derivatives, substituted in the direct vicinity of the nitrogen atom with a carboxylic acid group, can be treated as an expanded version of natural α-amino acid-based iGluR agonists such as glutamate or kainate, but with the α-amino group involved in the cyclic system. Compounds with this scaffold constitute a significant class of competitive AMPAR/KAR antagonists and usually possess a flexible linker with an attached distal acidic group, most often the tetrazolyl or carboxyl group.
One of the first compounds reported among this chemical class, acting as a competitive antagonist of AMPA/GluK1 receptors with micromolar affinity, was LY215490. Its stereoisomer LY293558 (26, tezampanel, Figure 3) was found to produce pain relief after oral surgery and in migraine patients and has undergone phase II clinical trials in patients with acute migraine [112,113,114][43][44][45]. Recent studies using rats exposed to soman also revealed its antiepileptic and neuroprotective efficacy after acute exposure to nerve agents and other organophosphate compounds both in monotherapy and in coadministration with other substances. In vivo studies with immature, young-adult, and aged rats exposed to soman demonstrated that 26 provided protection against brain impairment, prevented long-term behavioral deficits, and terminated status epilepticus, even with 1 h postexposure administration of tezampanel. In addition, full neuroprotection was achieved after simultaneous therapy with the NMDAR antagonist, caramiphen [115,116][46][47].
Ijms 24 01908 g005 550
Figure 3. Structures of cis-decahydroisoquinoline-derived KAR antagonists.
Competitive antagonists with improved selectivity for kainate receptors have been developed to enhance neuroprotective properties and efficacy in pain conditions with an improved side-effect profile [117][48]. The selective GluK1 antagonist LY377770 (27) demonstrated neuroprotective effects in models of global and focal ischemia at doses of 80 mg/kg administered intraperitoneally (i.p.) followed by 40 mg/kg i.p. 3–6 h after the initial dose [118][49]. The compounds LY377770 and LY382884 (28) blocked epileptic activity in hippocampal slices and in vivo limbic seizures in conscious rats induced by pilocarpine or 6 Hz corneal stimulation [119][50]. The study of the effect on formalin-induced pain behavior demonstrated the antinociceptive efficacy of LY382884 without ataxia at doses of 5, 10, 30, and 100 mg/kg i.p. [120][51]. Meanwhile, in a primate model of peripheral neuropathy, 28 injected into the dorsal horn of the spinal cord via microdialysis (at a concentration of 100 μM–10 mM) reduced the nociceptive responses and in a concentration-dependent manner attenuated the response to mechanical stimuli [121][52].
The improvement in oral bioavailability was achieved by preparing a diethyl ester for the selective GluK1 receptor antagonist (29). The resulting prodrug (30) showed a high oral efficacy in two animal migraine models. In the neurogenic plasma protein extravasation (PPE) model, 30 administered orally (p.o.) 1 h before trigeminal stimulation exhibited efficacy with an estimated ID50 = 100 pg/kg, while, in the nucleus caudalis c-fos expression model, 1 h of pretreatment with a dose of 10 mg/kg resulted in an approximately 30% decrease in the central Fos expression. Furthermore, 29 in the PPE model administered intravenously (i.v.) 10 min before stimulation demonstrated efficacy with an estimated ID50 of 0.03 pg/kg [122][53].
A particularly interesting example of a potent and selective antagonist was LY466195 (31) [123[54][55],124], which has been found to have more than a 100-fold selectivity for GluK1 over other kainate and AMPA receptor subtypes. Both LY466195 and the diethyl ester prodrug showed significant inhibitory effects in two preclinical models of migraine (31 administered i.v. and its ester administered p.o. in the PPE model exhibited an estimated ID50 of 100 μg/kg, while in the c-fos essay 31 demonstrated efficacy at doses of 1 to 100 μg/kg i.v. and its prodrug above a dose of 100 μg/kg). Compound 31 also demonstrated a lack of vasoconstrictive properties in the rabbit saphenous vein, suggesting that the vasoconstrictive properties of triptan molecules are not required for efficacy in PPE or c-fos assays [123][54].
Further improvement of the in vitro profile was achieved by the introduction of an oxygen linker and phenyl substituent in tetrazole derivatives. The most active compounds in the series, LY458545 (32) and LY457691 (33), showed a strong antagonism toward the AMPA and GluK1 receptors, but exhibited poor oral bioavailability. On the contrary, their prodrugs showed bioavailability levels of 24% and 41%, respectively, and both ester prodrugs showed oral efficacy in three animal models of pain. In the formalin test, prodrugs demonstrated efficacy at doses starting from 3 mg/kg and 5 mg/kg p.o., respectively. Furthermore, both compounds affected the dose-dependent reversal of carrageenan-induced thermal hyperalgesia with minimum effective doses (MED) of 1.0 mg/kg and 3.0 mg/kg p.o., and dose-dependent reverse capsaicin-induced mechanical hyperalgesia with MED of 1.0 and 10 mg/kg p.o., respectively [56].
Further enhancement of the selectivity and affinity for the GluK1 receptors was achieved by evaluating the structure of earlier tetrazole derivatives and introducing a chlorine substituent to obtain LY545694 (34). The 2-ethylbutyl ester of LY 545,694 showed a bioavailability of 42% in rats after oral administration and was shown to be effective in two animal models of persistent pain (dose-dependent reversal of carrageenan-induced thermal hyperalgesia with MED of 3 mg/kg p.o. and formalin model with MED of 1 mg/kg p.o.) [125][57]. The LY545694 tosylate has been studied in phase II of clinical trials for the treatment of pain caused by osteoarthritis of the knee (OA) and diabetic neuropathic pain (DPNP) [126][58].
The binding mode of the decahydroisoquinoline derivatives in the GluK1 receptor has been studied in the examples of the X-ray structures of the GluK1-LBD complexes with compounds 31 or 34 [124,125][55][57]. In both cases, the interactions of the ligand α-amino acid group involved in the isoquinoline system with the residues of the binding pocket resembled the canonical interactions previously observed for agonists and competitive antagonists with free α-amino acid functionality, e.g., willardiine derivatives.

1.3. Other α-Amino Acid Antagonists

The good example of this group are α-amino acids designed as expended versions of the natural iGluR agonist AMPA, with a structure based on the isoxazole core. Compounds in this series were designed primarily as competitive antagonists of the AMPA receptor (see the reviews of Nikam [83][16] and Catarzi [82][15]), and studies often lack data on the affinity at the kainate receptors. In this regard, one of the most developed compounds in this group is (S)-ATPO (35), the selective AMPAR/GluK1 antagonist that shows an affinity in the low micromolar range for the homomeric GluK1 receptors (Figure 4) [128,129][59][60]. Analysis of the X-ray structure of ATPO in complex with GluK1 revealed that, in addition to the typical binding mode of the α-amino acid group, seen for other α-amino acid agonists and antagonists in GluK1- or GluA2-LBD, (S)-ATPO also interacts with its phosphonate tail, forming hydrogen bonds with the non-conserved serine of GluK1, which probably accounts for the observed selectivity profile of the compound [130][61].
Ijms 24 01908 g006 550
Figure 4. Structures of selected α-amino acid antagonists of kainate receptors. * the stereoisomeric center in the molecule.
Furthermore, the isoxazole ring of (S)-ATPO does not form any specific interactions with the receptor, acting mainly as a spacer between the α-amino acid group and the phosphonate functionality. Therefore, the structure of (S)-ATPO became an inspiration for a series of phenylalanine-based AMPAR/KAR antagonists, in which the isoxazole spacer has been replaced by the benzene ring, substituted with the 2-carboxyethyl chain (36) [131,132][62][63]. The antagonist 36 showed an equimolar affinity at the native AMPA receptors and homomeric GluK1 receptors in the range of 3 μM and was cocrystallized with the AMPA subunit GluA2-LBD, as well as with the kainate subunit GluK1-LBD, inducing in both X-ray complexes a domain closure similar to that observed in the iGluR structures with partial agonists. The binding mode of 36 for both receptors resembled the binding modes of the (S)-ATPO and willardiine-based antagonists, with the canonical interaction pattern between the α-amino acid group and the arginine, proline, and threonine residues of the domain 1, conserved among all the non-NMDA subunits. Furthermore, an additional interaction between the nitro group and the Ser721 side chain (which, together with Glu441, forms the so-called ‘interdomain lock’ stabilizing the active state of the receptor), was suggested as an important determinant of ligand affinity.
Another series of phenylalanines reported by the same group was based on the biphenylalanine core substituted with the distal acidic group, either carboxy or phenolic hydroxy substituent (37, 38) [133,134,135][64][65][66]. Interestingly, it appeared that this distal polar group had a strong influence on the iGluR affinity profile: compounds with a 3-carboxy group attached to the distal phenyl ring (37) preferentially bound to GluK1 receptors (with a 35-fold selectivity over AMPAR in the case of 37), while the 3-hydroxy group at this position was optimal for binding to native AMPA receptors (38) (with a selectivity of 21 times over GluK1 receptors in the case of 38).
The structure of kainic acid became an inspiration for the design of a series of proline derivatives that contained an additional carboxyl group in their structure. The first structure described in this series, 39, demonstrated a micromolar affinity at the homomeric GluK1 receptor with a 20-fold selectivity over the homomeric GluK2 and GluK3 receptors (Table 4) [136][67]. Further modifications of the structure resulted in the improved selectivity and affinity at the homomeric GluK1 receptors (41, 42) [111[68][69],137], while, in the case of 40, the resulting compound exhibited a 5-fold increased affinity at the GluK3 subunit compared to the GluK1 subunit [137,138,139][69][70][71]. The X-ray structures of the GluK1-LBD cocrystallized with 41 or 42 were successfully resolved, which allowed for determining the binding mode of the proline derivatives in the binding pocket [111,137][68][69]. The α-amino acid moiety of the ligands interacted with the LBD residues in a manner similar to that described above.
Dysiherbaine derivatives belong to a group of active KAR ligands originally isolated from the marine sponge Lendenfeldia chodrodes. The synthetic derivative MSVIII-19 (43) was the first to demonstrate strong and selective antagonistic properties toward GluK1 homomeric receptors, with no affinity for GluA2 receptors [140,141,142][72][73][74]. Compound 43 showed analgesic activity in animal model studies, supporting the thesis of the potential of GluK1 antagonists in the treatment of pain [143][75]. The structural variants of neodysiherbaine (44) [144][76] did not show an improved affinity and selectivity for kainate receptors, compared to 43, but led to useful tools for studying the structure of KAR subunits [145][77].
In the group of bicyclic pyrimidine-2,4-dione analogs, on the other hand, subsequent structural adjustments have resulted in compound 45, which exhibited a remarkable selectivity for kainate receptors, especially the GluK1 subunit (over a 400-fold higher affinity for GluK1 compared to GluA2 and 53 times versus GluK3). Functional studies confirmed the antagonist profile of 45, while the in vivo mouse formalin test of prolonged acute pain stimulation proved its analgesic efficacy at a dose of 2 mg/kg [146][78]. The molecular interactions observed in the crystal structure resolved for 45 in complex with the GluK1-LBD correspond to those previously observed for other willardiine derivatives [147][79]. In particular, the carboxyl group of the amino acid moiety forms an ion pair interaction with the side chain of Arg523 (Arg508 according to residue numbering in ref. [104][35]), and a hydrogen bond with the backbone of Thr518 (Thr503), while the α-amino group is involved in multiple H-bond contacts with the carbonyl group of Pro516 (Pro501), the side chain of Thr518, and, additionally, with the Glu738 of domain 2. On the other hand, the flexible carboxythienyl part of molecule 45 interacts with the residues of domain 2 of the GluK1-LBD, thus stabilizing an open conformation of the binding pocket [147][79].
(S)-mercaptohistidine (46) represents one of the first selective GluK3 receptor antagonists described, with a 30-fold affinity preference over GluK1, GluA3, and GluA4 and a selectivity of more than 100-fold over the recombinant receptors GluK2, GluA1, and GluA2, determined in radioligand binding assays. Surprisingly, the functional evaluation revealed antagonistic activity for the GluK3 receptors, but also weak agonist activity for the GluA2 receptors, making 46 the first orthosteric iGluRs ligand with a mixed agonist–antagonist profile for KARs/AMPARs [148][80].

1.34. Structurally Dissimilar AMPAR/KAR Antagonists

In addition to the chemical classes described above, some structurally dissimilar competitive antagonists of AMPA/KA receptors with in vivo anticonvulsant activity have been identified [149][81], including quinazoline-2,4-diones (47 and BGG492, selurampanel, 48) [150[82][83],151], isatin oximes (NS 1209, 49) [152[84][85],153], and derivatives of pyrazine (RPR117824, 50, Figure 5) [154,155][86][87]. NS 1209 showed potent and dose-dependent anticonvulsant activity in various preclinical models and alleviated refractory status epilepticus and neuropathic pain in phase II of clinical trials, but further research on the molecule has been suspended [153,156][85][88]. RPR117824 in in vivo models blocked convulsions induced in mice or rats by supramaximal electroshock or chemoconvulsive agents such as pentylenetetrazol and showed significant neuroprotective activity in global and focal cerebral ischemia and brain and spinal cord trauma [154,155][86][87]. In the group of quinazoline-2,4-dione derivatives, compound 47 showed a high affinity for native KA receptors and demonstrated neuroprotective effects in an in vitro model of cerebral ischemia [157,158][89][90]. BGG 492 (selurampanel), an orally active AMPAR/KAR antagonist (the functional efficacy on the rat cortical wedge for the AMPAR and KAR was 0.46 and 0.42 μM, respectively), has shown anticonvulsant activity in animal models of epilepsy, such as electroshock or chemically induced seizures in rodents. Currently, 48 has been subjected to clinical trials aimed at patients with epilepsy, tinnitus, and migraine [150][82].
Ijms 24 01908 g007 550
Figure 5. Structurally dissimilar AMPAR/KAR antagonists.

2. Non-Competitive Antagonists and Channel Blockers of Kainate Receptors

Despite the fact that the pharmacology of non-competitive inhibitors of AMPA and kainate receptors remains very similar, AMPAR antagonists have attracted more interest in recent years, especially as antiepileptic agents. Among them, a certain number of compounds likely act as non-selective AMPAR/KAR inhibitors, and only a few examples of selective kainate receptor non-competitive antagonists have been described.
The early described group of non-competitive antagonists of non-NMDA receptors, 2,3-benzodiazepine derivatives, are widely recognized as selective AMPAR antagonists with very low potency and efficacy for kainate receptors. Considering that members of this chemical class selectively block AMPAR-conducted responses, some of them are used as pharmacological tools to isolate the corresponding neuronal response from kainate receptors. The compound GYKI 53,655 (51, Figure 6) was shown not to affect GluK1 or GluK2-containing kainate receptors or native somatodendritic kainate receptors (IC50 > 200 mM) [16,23,160][38][91][92]. However, in the case of GluK3-containing receptors expressed in HEK 293 cells, GYKI 53,655 was able to block currents from activated GluK3 homomeric receptors with an IC50 = 63 ± 10 µM, and from GluK2/3 heteromeric receptors with an even better result, IC50 = 32 ± 5 µM. Furthermore, at high concentrations, the compound was found to block presynaptic kainate receptors in mossy fiber synapses (likely composed of GluK2/3 heteromers) and decrease short-term plasticity [23][38].
Ijms 24 01908 g008 550
Figure 6. Non-competitive antagonists and channel blockers of kainate receptors.
A real breakthrough in iGluR research was the development of perampanel (52, Fycompa, Figure 6), approved as an oral drug for partial-onset seizures and generalized primary tonic–clonic seizures [164][93]. Initial studies showed that 52 inhibits native AMPA receptors and also individual AMPAR subunits with no affinity for NMDARs and KARs [165][94]. However, recent structural studies of AMPARs in complex with perampanel have shown that its binding site consists of amino acids that are also highly conserved for the GluK4 and GluK5 receptor subunits. Consequently, contrary to previous assumptions, 52 demonstrated the effective inhibition of the heteromeric GluK1/5 and GluK2/5 receptors at levels comparable to the native AMPA receptors. Furthermore, the presence of NETO1 and NETO2 was shown to significantly affect KAR affinity, particularly heteromers containing the GluK2 subunit [166][95]. Perampanel has been included in a wide range of clinical trials for epilepsy among children and adults [164[93][96][97][98][99][100][101][102][103][104],167,168,169,170,171,172,173,174,175], as well as in studies for Parkinson’s disease [176,177][105][106] or amyotrophic lateral sclerosis [178,179][107][108].
The non-selective inhibitory effect of kainate receptors was also observed in the case of cis-unsaturated fatty acids. In contrast to fully saturated fatty acids, docosahexaenoic acid (DHA), arachidonic acid (AA), linolenic acid, and linoleic acid demonstrated a significant reduction in kainate-induced whole cell currents and reversibly inhibited kainate receptor signaling by acting within the TMD [180,181,182][109][110][111].
A group that has contributed to a better understanding of the physiology and pathophysiology of kainate receptors [183,184][112][113] is arylureidobenzoic acids, in particular 4,6-bis (benzylamine)-1,3- benzenedicarboxylic acid (NS 3763, 53), which is a selective antagonist of the homomeric GluK1 receptor, lacking an affinity for the native AMPAR and GluK1/2 and GluK1/5 heteromers [162,183,185,186][112][114][115][116]. Proceeding with research on selective kainate receptor inhibitors, the group of Kaczor et al. reported 1,2,3,5-tetrasubstituted indole derivatives, including the first non-competitive GluK2 receptor ligand known so far (54) [163][117]. Studies on these derivatives have contributed to the development of computational research on the structure of kainate receptor subunits and ligand binding sites [163,187,188][117][118][119].
A drug whose exact mode of action has not yet been clarified is topiramate (55). Its potent neuroprotective and anticonvulsant effect has been confirmed by several studies using animal models, and at least three mechanisms appear to contribute to this action profile: (1) enhancement of the GABA response; (2) blocking voltage-dependent ion channels, and (3) inhibition of AMPA/KA receptors [189][120]. Meanwhile, topiramate has been shown to be ineffective against AMPA- or NMDA-induced clonic seizures, but it is effective in blocking kainate-induced seizures [190,191][121][122]. Subsequent in vivo studies investigating the blocking of the agonist-induced seizure activity of iGluRs confirmed that topiramate selectively inhibits the GluK1 subunit response [190,192][121][123]. For its unique properties, topiramate is used as a treatment for epilepsy with partial and generalized tonic–clonic seizures, as well as for migraine prevention and treatment. In addition to this, several clinical trials have been conducted for the treatment of eating disorders, obesity, alcohol dependence, neuropathy, post-traumatic stress disorder, and Tourette syndrome [38][124].
Inhibition of iGluR activity could also occur as a result of the binding of ion channel blockers. Among this group of derivatives, many naturally occurring compounds, as well as their synthetic analogs, have been described. All shared structural similarity (that is, polyamine moiety) and, when applied, blocked the AMPAR/KAR in a voltage-independent manner [193][125]. Within the KAR family, the GluK3 subunit demonstrated significant sensitivity to polyamines, especially compared to the GluK1 and GluK2 subunits. Meanwhile, auxiliary proteins of the kainate receptors, NETO1 and NETO2, attenuated the blocking of ion channels [194][126]. As mentioned above, permeability to Ca2+ as well as an affinity of polyamines is related to the editing of the Q/R site, where the kainate receptors of the “R” type are not permeable to Ca2+ and show no sensitivity to polyamines [16,17,195][91][127][128]. This effect was considered to derive from the electrostatic repulsive effect of positively charged arginine in the narrowest region of the pore. GluK4- and GluK5-containing heteromers have also been found to weaken polyamine blocking due to the presence of a proline residue that is not represented in the GluK1-3 subunits and changes the dynamics of the α-helical region of the selectivity filter [2,194,196,197][126][129][130][131].
Studies using the toxin of the spider venom Argiope lobata (ArgTX-636, 56) [195][128], the Joro spider toxin (JSTX-3, 57) [196][130], the agatotoxin of the North American funnel web spider Ageleonopsis aperta (AGEL-489, 58 and AGEL-505, 59) [198][132], or the active venom fraction of Philanthus triangulum (PhTX-433, 60) [199][133] demonstrated that polyamines are not only potent antagonists of ionotropic glutamate receptors, but can also exhibit other biological activities [200,201,202,203,204,205][134][135][136][137][138][139]. Synthetic derivatives of philanthotoxins allowed for determining structure–activity relationships, principally concerning AMPA receptors. The modification that resulted in an active blocking of the GluK1 subunit (PhTX-47, 61, Ki = 0.060 ± 0.014 μM) involved altering the length of the polyamine chain with respect to the number of amine groups and the methylene bridges located between them. In contrast, even a slight modification of the chain length shifted activity at the GluA1 receptors (PhTX-56, 62) with affinity at the GluA1 subunits of Ki = 3.3 ± 0.78 nM [203][137].
Other synthetic polyamine derivatives, IEM-1460 (63) [206][140] and N1-naphthylacetylspermine (64) [207][141], predominantly affect the GluA2-deficient Ca2+ receptors and further studies have shown that modifications of both the polyamine chain and the head group can contribute to changes in activity and selective affinity at the AMPA, KA, and NMDA receptors [208,209,210,211][142][143][144][145].

References

  1. Honoré, T.; Davies, S.N.; Drejer, J.; Fletcher, E.J.; Jacobsen, P.; Lodge, D.; Nielsen, F.E. Quinoxalinediones: Potent competitive non-NMDA glutamate receptor antagonists. Science 1988, 241, 701–703.
  2. Sheardown, M.J.; Nielsen, E.O.; Hansen, A.J.; Jacobsen, P.; Honore, T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: A neuroprotectant for cerebral ischemia. Science 1990, 247, 571–574.
  3. Judge, M.E.; Sheardown, M.J.; Jacobsen, P.; Honoré, T. Protection against post-ischemic behavioral pathology by the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) in the gerbil. Neurosci. Lett. 1991, 133, 291–294.
  4. Lubisch, W.; Behl, B.; Hofmann, H.P. Amido-Quinoxalinediones, the Preparation and Use Thereof. U.S. Patent 5,773,439, 30 June 1998.
  5. Löscher, W.; Lehmann, H.; Behl, B.; Seemann, D.; Teschendorf, H.J.; Hofmann, H.P.; Lubisch, W.; Höger, T.; Lemaire, H.G.; Gross, G. A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: Pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy. Eur. J. Neurosci. 1999, 11, 250–262.
  6. Twele, F.; Bankstahl, M.; Klein, S.; Römermann, K.; Löscher, W. The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. Neuropharmacology 2015, 95, 234–242.
  7. Lippman-Bell, J.J.; Rakhade, S.N.; Klein, P.M.; Obeid, M.; Jackson, M.C.; Joseph, A.; Jensen, F.E. AMPA Receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizures. Epilepsia 2013, 54, 1922–1932.
  8. Kong, L.-L.; Yu, L.-C. It is AMPA receptor, not kainate receptor, that contributes to the NBQX-induced antinociception in the spinal cord of rats. Brain Res. 2006, 1100, 73–77.
  9. Van Damme, P.; Leyssen, M.; Callewaert, G.; Robberecht, W.; Van Den Bosch, L. The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 2003, 343, 81–84.
  10. Goda, M.; Isono, M.; Fujiki, M.; Kobayashi, H. Both MK801 and NBQX reduce the neuronal damage after impact-acceleration brain injury. J. Neurotrauma 2002, 19, 1445–1456.
  11. Follett, P.L.; Rosenberg, P.A.; Volpe, J.J.; Jensen, F.E. NBQX attenuates excitotoxic injury in developing white matter. J. Neurosci. 2000, 20, 9235–9241.
  12. Swedberg, M.D.; Jacobsen, P.; Honoré, T. Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX). J. Pharmacol. Exp. Ther. 1995, 274, 1113–1121.
  13. Matsuoka, Y.; Kitamura, Y.; Tsukahara, T.; Terai, K.; Tooyama, I.; Kimura, H.; Taniguchi, T. Neuroprotective effects of NBQX on hypoxia-induced neuronal damage in rat hippocampus. Neuroreport 1995, 6, 2205–2208.
  14. Löscher, W.; Hönack, D. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: Comparison with diazepam and interactions with flumazenil. Br. J. Pharmacol. 1994, 113, 1349–1357.
  15. Catarzi, D.; Colotta, V.; Varano, F. Competitive AMPA receptor antagonists. Med. Res. Rev. 2007, 27, 239–278.
  16. Nikam, S.S.; Kornberg, B.E. AMPA receptor antagonists. Curr. Med. Chem. 2001, 8, 155–170.
  17. Larsen, A.M.; Bunch, L. Medicinal chemistry of competitive kainate receptor antagonists. ACS Chem. Neurosci. 2011, 2, 60–74.
  18. Shimizu-Sasamata, M.; Kawasaki-Yatsugi, S.; Okada, M.; Sakamoto, S.; Yatsugi, S.; Togami, J.; Hatanaka, K.; Ohmori, J.; Koshiya, K.; Usuda, S.; et al. YM90K: Pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist. J. Pharmacol. Exp. Ther. 1996, 276, 84–92.
  19. Takahashi, M.; Kohara, A.; Shishikura, J.; Kawasaki-Yatsugi, S.; Ni, J.W.; Yatsugi, S.; Sakamoto, S.; Okada, M.; Shimizu-Sasamata, M.; Yamaguchi, T. YM872: A selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist. CNS Drug Rev. 2002, 8, 337–352.
  20. Furukawa, T.; Hoshino, S.; Kobayashi, S.; Asakura, T.; Takahashi, M.; Atsumi, T.; Teramoto, A. The glutamate AMPA receptor antagonist, YM872, attenuates cortical tissue loss, regional cerebral edema, and neurological motor deficits after experimental brain injury in rats. J. Neurotrauma 2003, 20, 269–278.
  21. Turski, L.; Huth, A.; Sheardown, M.J.; McDonald, F.; Neuhaus, R.; Schneider, H.H.; Dirnagl, U.; Wiegand, F.; Jacobsen, P.; Ottow, E. ZK200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc. Natl. Acad. Sci. USA 1998, 95, 10960–10965.
  22. Terai, K.; Suzuki, M.; Sasamata, M. Therapeutic Agent for Brain Hemorrhage. WO2004002488, 8 January 2004.
  23. Ishiuchi, S. Remedy for Glioblastoma. CA2479495, 9 October 2003.
  24. Pallesen, J.; Møllerud, S.; Frydenvang, K.; Pickering, D.S.; Bornholdt, J.; Nielsen, B.; Pasini, D.; Han, L.; Marconi, L.; Kastrup, J.S.; et al. N1-substituted quinoxaline-2,3-diones as kainate receptor antagonists: X-ray crystallography, structure−affinity relationships, and in vitro pharmacology. ACS Chem. Neurosci. 2019, 10, 1841–1853.
  25. Madsen, U.; Stensbol, T.; Krogsgaard-Larsen, P. Inhibitors of ampa and kainate receptors. Curr. Med. Chem. 2012, 8, 1291–1301.
  26. Lubisch, W.; Behl, B.; Henn, C.; Hofmann, H.P.; Reeb, J.; Regner, F.; Vierling, M. Pyrrolylquinoxalinediones carrying a piperazine residue represent highly potent and selective ligands to the homomeric kainate receptor GluR5. Bioorg. Med. Chem. Lett. 2002, 12, 2113–2116.
  27. Møllerud, S.; Hansen, R.B.; Pallesen, J.; Temperini, P.; Pasini, D.; Bornholt, J.; Nielsen, B.; Mamedova, E.; Chalupnik, P.; Paternain, A.V.; et al. N-(7-(1H-Imidazol-1-yl)-2,3-dioxo-6-(trifluoromethyl)-3,4-dihydroquinoxalin-1(2H)-yl)benzamide, a new kainate receptor selective antagonist and analgesic: Synthesis, X-ray crystallography, structure-affinity relationships, and in vitro and in vivo pharmacology. ACS Chem. Neurosci. 2019, 10, 4685–4695.
  28. Møllerud, S.; Frydenvang, K.; Pickering, D.S.; Kastrup, J.S. Lessons from crystal structures of kainate receptors. Neuropharmacology 2017, 112, 16–28.
  29. Pøhlsgaard, J.; Frydenvang, K.; Madsen, U.; Kastrup, J.S. Lessons from more than 80 structures of the GluA2 ligand-binding domain in complex with agonists, antagonists and allosteric modulators. Neuropharmacology 2011, 60, 135–150.
  30. Chałupnik, P.; Vialko, A.; Pickering, D.S.; Hinkkanen, M.; Donbosco, S.; Møller, T.C.; Jensen, A.A.; Nielsen, B.; Bay, Y.; Kristensen, A.S.; et al. Discovery of the first highly selective antagonist of the GluK3 kainate receptor subtype. Int. J. Mol. Sci. 2022, 23, 8797.
  31. Demmer, C.S.; Møller, C.; Brown, P.M.; Han, L.; Pickering, D.S.; Nielsen, B.; Bowie, D.; Frydenvang, K.; Kastrup, J.S.; Bunch, L. Binding mode of an α-amino acid-linked quinoxaline-2,3-dione analogue at glutamate receptor subtype GluK1. ACS Chem. Neurosci. 2015, 6, 845–854.
  32. Demmer, C.S.; Rombach, D.; Liu, N.; Nielsen, B.; Pickering, D.S.; Bunch, L. Revisiting the quinoxalinedione scaffold in the construction of new ligands for the ionotropic glutamate receptors. ACS Chem. Neurosci. 2017, 8, 2477–2495.
  33. More, J.C.A.; Troop, H.M.; Dolman, N.P.; Jane, D.E. Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. Br. J. Pharmacol. 2003, 138, 1093–1100.
  34. More, J.C.A.; Nistico, R.; Dolman, N.P.; Clarke, V.R.J.; Alt, A.J.; Ogden, A.M.; Buelens, F.P.; Troop, H.M.; Kelland, E.E.; Pilato, F.; et al. Characterisation of UBP296: A novel, potent and selective kainate receptor antagonist. Neuropharmacology 2004, 47, 46–64.
  35. Mayer, M.L.; Ghosal, A.; Dolman, N.P.; Jane, D.E. Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists. J. Neurosci. 2006, 26, 2852–2861.
  36. Dolman, N.P.; More, J.C.; Alt, A.; Knauss, J.L.; Pentikainen, O.T.; Glasser, C.R.; Bleakman, D.; Mayer, M.L.; Collingridge, G.L.; Jane, D.E. Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: Role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists. J. Med. Chem. 2007, 50, 1558–1570.
  37. Jane, D.E.; Lodge, D.; Collingridge, G.L. Kainate receptors: Pharmacology, function and therapeutic potential. Neuropharmacology 2009, 56, 90–113.
  38. Perrais, D.; Pinheiro, P.S.; Jane, D.E.; Mulle, C. Antagonism of recombinant and native GluK3-containing kainate receptors. Neuropharmacology 2009, 56, 131–140.
  39. Lique Peret, A.; Christie, L.A.; Ouedraogo, D.W.; Gorlewicz, A.; Rô Me Epsztein, J.; Mulle, C.; Rie Cré Pel, V. Contribution of aberrant GluK2-containing kainate receptors to chronic seizures in temporal lobe epilepsy. Cell Rep. 2014, 8, 347–354.
  40. Stayte, S.; Laloli, K.J.; Rentsch, P.; Lowth, A.; Li, K.M.; Pickford, R.; Vissel, B. The kainate receptor antagonist UBP310 but not single deletion of GluK1, GluK2, or GluK3 subunits, inhibits MPTP-induced degeneration in the mouse midbrain. Exp. Neurol. 2020, 323, 113062.
  41. Pollok, S.; Reiner, A. Subunit-selective iGluR antagonists can potentiate heteromeric receptor responses by blocking desensitization. Proc. Natl. Acad. Sci. USA 2020, 117, 25851–25858.
  42. Dargan, S.L.; Clarke, V.R.J.; Alushin, G.M.; Sherwood, J.L.; Nisticò, R.; Bortolotto, Z.A.; Ogden, A.M.; Bleakman, D.; Doherty, A.J.; Lodge, D.; et al. ACET is a highly potent and specific kainate receptor antagonist: Characterisation and effects on hippocampal mossy fibre function. Neuropharmacology 2009, 56, 121–130.
  43. Gilron, I.; Max, M.B.; Lee, G.; Booher, S.L.; Sang, C.N.; Chappell, A.S.; Dionne, R.A. Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin. Pharmacol. Ther. 2000, 68, 320–327.
  44. Sang, C.N.; Hostetter, M.P.; Gracely, R.H.; Chappell, A.S.; Schoepp, D.D.; Lee, G.; Whitcup, S.; Caruso, R.; Max, M.B. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 1998, 89, 1060–1067.
  45. Lee, H.J.; Pogatzki-Zahn, E.M.; Brennan, T.J. The effect of the AMPA/kainate receptor antagonist LY293558 in a rat model of postoperative pain. J. Pain Palliat. Care Pharmacother. 2006, 7, 768–777.
  46. Aroniadou-Anderjaska, V.; Figueiredo, T.H.; Apland, J.P.; Braga, M.F. Targeting the glutamatergic system to counteract organophosphate poisoning: A novel therapeutic strategy. Neurobiol. Dis. 2020, 133, 104406.
  47. Figueiredo, T.H.; Qashu, F.; Apland, J.P.; Aroniadou-Anderjaska, V.; Souza, A.P.; Braga, M.F.M. The GluK1 (GluR5) kainate/ -amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J. Pharmacol. Exp. Ther. 2011, 336, 303–312.
  48. Martinez-Perez, J.A.; Iyengar, S.; Shannon, H.E.; Bleakman, D.; Alt, A.; Arnold, B.M.; Bell, M.G.; Bleisch, T.J.; Castaño, A.M.; Del Prado, M.; et al. GluK1 antagonists from 6-(carboxy)phenyl decahydroisoquinoline derivatives. SAR and evaluation of a prodrug strategy for oral efficacy in pain models. Bioorg. Med. Chem. Lett. 2013, 23, 6459–6462.
  49. O’Neill, M.J.; Bogaert, L.; Hicks, C.A.; Bond, A.; Ward, M.A.; Ebinger, G.; Ornstein, P.L.; Michotte, Y.; Lodge, D. LY377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia. Neuropharmacology 2000, 39, 1575–1588.
  50. Smolders, I.; Bortolotto, Z.A.; Clarke, V.R.; Warre, R.; Khan, G.M.; O’Neill, M.J.; Ornstein, P.L.; Bleakman, D.; Ogden, A.; Weiss, B.; et al. Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat. Neurosci. 2002, 5, 796–804.
  51. Simmons, R.M.; Li, D.L.; Hoo, K.H.; Deverill, M.; Ornstein, P.L.; Iyengar, S. Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology 1998, 37, 25–36.
  52. Palecek, J.; Neugebauer, V.; Carlton, S.M.; Iyengar, S.; Willis, W.D. The effect of a kainate GluR5 receptor antagonist on responses of spinothalamic tract neurons in a model of peripheral neuropathy in primates. Pain 2004, 111, 151–161.
  53. Filla, S.A.; Winter, M.A.; Johnson, K.W.; Bleakman, D.; Bell, M.G.; Bleisch, T.J.; Castaño, A.M.; Clemens-Smith, A.; Del Prado, M.; Dieckman, D.K.; et al. Ethyl (3s,4aR,6S,8aR)-6-(4-ethoxycar-bonylimidazol-1-ylmethyl) decahydroiso-quinoline-3-carboxylic ester: A prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine. J. Med. Chem. 2002, 45, 4383–4386.
  54. Weiss, B.; Alt, A.; Ogden, A.M.; Gates, M.; Dieckman, D.K.; Clemens-Smith, A.; Ho, K.H.; Jarvie, K.; Rizkalla, G.; Wright, R.A.; et al. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J. Pharmacol. Exp. Ther. 2006, 318, 772–781.
  55. Alushin, G.M.; Jane, D.; Mayer, M.L. Binding site and ligand flexibility revealed by high resolution crystal structures of GluK1 competitive antagonists. Neuropharmacology 2011, 60, 126–134.
  56. Dominguez, E.; Iyengar, S.; Shannon, H.E.; Bleakman, D.; Alt, A.; Arnold, B.M.; Bell, M.G.; Bleisch, T.J.; Buckmaster, J.L.; Castano, A.M.; et al. Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain. J. Med. Chem. 2005, 48, 4200–4203.
  57. Martinez-Perez, J.A.; Iyengar, S.; Shannon, H.E.; Bleakman, D.; Alt, A.; Clawson, D.K.; Arnold, B.M.; Bell, M.G.; Bleisch, T.J.; Castaño, A.M.; et al. GluK1 antagonists from 6-(tetrazolyl)phenyl decahydroisoquinoline derivatives: In vitro profile and in vivo analgesic efficacy. Bioorg. Med. Chem. Lett. 2013, 23, 6463–6466.
  58. Chappell, A.S.; Iyengar, S.; Lobo, E.D.; Prucka, W.R. Results from clinical trials of a selective ionotropic glutamate receptor 5 (iGluR5) antagonist, LY5454694 tosylate, in 2 chronic pain conditions. Pain 2014, 155, 1140–1149.
  59. Madsen, U.; Bang-Andersen, B.; Brehm, L.; Christensen, I.T.; Ebert, B.; Kristoffersen, I.T.; Lang, Y.; Krogsgaard-Larsen, P. Synthesis and pharmacology of highly selective carboxy and phosphono isoxazole amino acid AMPA receptor antagonists. J. Med. Chem. 1996, 39, 1682–1691.
  60. Moller, E.H.; Egebjerg, J.; Brehm, L.; Stensbol, T.B.; Johansen, T.N.; Madsen, U.; Krogsgaard-Larsen, P. Resolution, absolute stereochemistry, and enantiopharmacology of the GluR1-4 and GluR5 antagonist 2-amino-3-propionic acid. Chirality 1999, 11, 752–759.
  61. Hald, H.; Naur, P.; Pickering, D.S.; Sprogøe, D.; Madsen, U.; Timmermann, D.B.; Ahring, P.K.; Liljefors, T.; Schousboe, A.; Egebjerg, J.; et al. Partial agonism and antagonism of the ionotropic glutamate receptor iGLuR5: Structures of the ligand-binding core in complex with domoic acid and 2-amino-3-propionic acid. J. Biol. Chem. 2007, 282, 25726–25736.
  62. Szymańska, E.; Frydenvang, K.; Contreras-Sanz, A.; Pickering, D.S.; Frola, E.; Serafimoska, Z.; Nielsen, B.; Kastrup, J.S.; Johansen, T.N. A new phenylalanine derivative acts as an antagonist at the AMPA receptor GluA2 and introduces partial domain closure: Synthesis, resolution, pharmacology, and crystal structure. J. Med. Chem. 2011, 54, 7289–7298.
  63. Venskutonyte, R.; Frydenvang, K.; Valades, E.A.; Szymańska, E.; Johansen, T.N.; Kastrup, J.S.; Pickering, D.S. Structural and pharmacological characterization of phenylalanine-based AMPA receptor antagonists at kainate receptors. ChemMedChem 2012, 7, 1793–1798.
  64. Szymanska, E.; Pickering, D.S.; Nielsen, B.; Johansen, T.N. 3-Substituted phenylalanines as selective AMPA- and kainate receptor ligands. Bioorg. Med. Chem. 2009, 17, 6390–6401.
  65. Szymańska, E.; Frydenvang, K.; Pickering, D.S.; Krintel, C.; Nielsen, B.; Kooshki, A.; Zachariassen, L.G.; Olsen, L.; Kastrup, J.S.; Johansen, T.N. Studies on aryl-substituted phenylalanines: Synthesis, activity, and different binding modes at AMPA receptors. J. Med. Chem. 2016, 59, 448–461.
  66. Szymańska, E.; Chałupnik, P.; Szczepańska, K.; Cuñado Moral, A.M.; Pickering, D.S.; Nielsen, B.; Johansen, T.N.; Kieć-Kononowicz, K. Design, synthesis and structure-activity relationships of novel phenylalanine-based amino acids as kainate receptors ligands. Bioorg. Med. Chem. Lett. 2016, 26, 5568–5572.
  67. Larsen, A.M.; Venskutonytè, R.; Valadés, E.A.; Nielsen, B.; Pickering, D.S.; Bunch, L. Discovery of a new class of ionotropic glutamate receptor antagonists by the rational design of (2 S,3 R)-3-(3-carboxyphenyl)-pyrrolidine-2-carboxylic acid. ACS Chem. Neurosci. 2011, 2, 107–114.
  68. Krogsgaard-Larsen, N.; Storgaard, M.; Møller, C.; Demmer, C.S.; Hansen, J.; Han, L.; Monrad, R.N.; Nielsen, B.; Tapken, D.; Pickering, D.S.; et al. Structure-activity relationship study of ionotropic glutamate receptor antagonist (2S,3R)-3-(3-carboxyphenyl)pyrrolidine-2-carboxylic acid. J. Med. Chem. 2015, 58, 6131–6150.
  69. Krogsgaard-Larsen, N.; Delgar, C.G.; Koch, K.; Brown, P.M.G.E.; Møller, C.; Han, L.; Huynh, T.H.V.; Hansen, S.W.; Nielsen, B.; Bowie, D.; et al. Design and synthesis of a series of l-trans-4-substituted prolines as selective antagonists for the ionotropic glutamate receptors including functional and X-ray crystallographic studies of new subtype selective kainic acid receptor subtype 1 (GluK1) antagonist (2S,4R)-4-(2-carboxyphenoxy)pyrrolidine-2-carboxylic acid. J. Med. Chem. 2017, 60, 441–457.
  70. Bunch, L. Pyrrolidine-2-Carboxylic Acid Derivatives as iGluR Antagonists. US20140235576A1, 21 August 2014.
  71. Bunch, L. Substituted 4-Proline Derivatives as iGluR Antagonists. WO2015003723A1, 15 January 2015.
  72. Sanders, J.M.; Ito, K.; Settimo, L.; Pentikäinen, O.T.; Shoji, M.; Sasaki, M.; Johnson, M.S.; Sakai, R.; Swanson, G.T. Divergent pharmacological activity of novel marine-derived excitatory amino acids on glutamate receptors. J. Pharmacol. Exp. Ther. 2005, 314, 1068–1078.
  73. Sanders, J.M.; Pentikäinen, O.T.; Settimo, L.; Pentikäinen, U.; Shoji, M.; Sasaki, M.; Sakai, R.; Johnson, M.S.; Swanson, G.T. Determination of binding site residues responsible for the subunit selectivity of novel marine-derived compounds on kainate receptors. Mol. Pharmacol. 2006, 69, 1849–1860.
  74. Frydenvang, K.; Lash, L.L.; Naur, P.; Postila, P.A.; Pickering, D.S.; Smith, C.M.; Gajhede, M.; Sasaki, M.; Sakai, R.; Pentikänen, O.T.; et al. Full domain closure of the ligand-binding core of the ionotropic glutamate receptor iGluR5 induced by the high affinity agonist dysiherbaine and the functional antagonist 8,9-dideoxyneodysiherbaine. J. Biol. Chem. 2009, 284, 14219–14229.
  75. Qiu, C.-S.; Lash-Van Wyhe, L.; Sasaki, M.; Sakai, R.; Swanson, G.T.; Gereau, R.W. Antinociceptive effects of MSVIII-19, a functional antagonist of the GluK1 kainate receptor. Pain 2011, 152, 1052–1060.
  76. Lash, L.L.; Sanders, J.M.; Akiyama, N.; Shoji, M.; Postila, P.; Pentikäinen, O.T.; Sasaki, M.; Sakai, R.; Swanson, G.T. Novel analogs and stereoisomers of the marine toxin neodysiherbaine with specificity for kainate receptors. J. Pharmacol. Exp. Ther. 2008, 324, 484–496.
  77. Swanson, G.T.; Lash, L.; Sakai, R. Kainate Receptor-Selective Epimeric Analogs of Dysiherbaine. U.S. Patent US20090118358A1, 5 July 2009.
  78. Brogi, S.; Brindisi, M.; Butini, S.; Kshirsagar, G.U.; Maramai, S.; Chemi, G.; Gemma, S.; Campiani, G.; Novellino, E.; Fiorenzani, P.; et al. (S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid (AMPA) and kainate receptor ligands: Further exploration of bioisosteric replacements and structural and biological investigation. J. Med. Chem. 2018, 61, 2124–2130.
  79. Venskutonyte, R.; Butini, S.; Coccone, S.S.; Gemma, S.; Brindisi, M.; Kumar, V.; Guarino, E.; Maramai, S.; Valenti, S.; Amir, A.; et al. Selective kainate receptor (GluK1) ligands structurally based upon 1H-cyclopentapyrimidin-2,4(1H3H)- dione: Synthesis, molecular modeling, and pharmacological and biostructural characterization. J. Med. Chem. 2011, 54, 4793–4805.
  80. Poulie, C.B.M.; Larsen, Y.; Leteneur, C.; Barthet, G.; Bjørn-Yoshimoto, W.E.; Malhaire, F.; Nielsen, B.; Pin, J.-P.; Mulle, C.; Pickering, D.S.; et al. (S)-2-Mercaptohistidine: A first selective orthosteric GluK3 antagonist. ACS Chem. Neurosci. 2022, 13, 1580–1587.
  81. Mula, M. Emerging drugs for focal epilepsy. Expert Opin. Emerg. Drugs 2013, 18, 87–95.
  82. Faught, E. BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opin. Investig. Drugs 2014, 23, 107–113.
  83. Orain, D.; Tasdelen, E.; Haessig, S.; Koller, M.; Picard, A.; Dubois, C.; Lingenhoehl, K.; Desrayaud, S.; Floersheim, P.; Carcache, D.; et al. Design and synthesis of Selurampanel, a novel orally active and competitive AMPA receptor antagonist. ChemMedChem 2017, 12, 197–201.
  84. Nielsen, E.O.; Varming, T.; Mathiesen, C.; Jensen, L.H.; Moller, A.; Gouliaev, A.H.; Wätjen, F.; Drejer, J. SPD 502: A water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity. J. Pharmacol. Exp. Ther. 1999, 289, 1492–1501.
  85. Keppel Hesselink, J.M. NS1209/SPD 502, a novel selective AMPA antagonist for stroke, neuropathic pain or epilepsy? Drug development lessons learned. Drug Dev. Res. 2017, 78, 75–80.
  86. Mignani, S.; Bohme, G.A.; Birraux, G.; Boireau, A.; Jimonet, P.; Damour, D.; Genevois-Borella, A.; Debono, M.W.; Pratt, J.; Vuilhorgne, M.; et al. 9-Carboxymethyl-5H,10H-imidazoindenopyrazin-4-one-2-carbocylic acid (RPR117824): Selective anticonvulsive and neuroprotective AMPA antagonist. Bioorg. Med. Chem. 2002, 10, 1627–1637.
  87. Krampfl, K.; Schlesinger, F.; Cordes, A.L.; Bufler, J. Molecular analysis of the interaction of the pyrazine derivatives RPR119990 and RPR117824 with human AMPA-type glutamate receptor channels. Neuropharmacology 2006, 50, 479–490.
  88. Gormsen, L.; Finnerup, N.B.; Almqvist, P.M.; Jensen, T.S. The efficacy of the AMPA receptor antagonist ns1209 and lidocaine in nerve injury pain: A randomized, double-blind, placebo-controlled, three-way crossover study. Anesth. Analg. 2009, 108, 1311–1319.
  89. Colotta, V.; Catarzi, D.; Varano, F.; Lenzi, O.; Filacchioni, G.; Costagli, C.; Galli, A.; Ghelardini, C.; Galeotti, N.; Gratteri, P.; et al. Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Synthesis, pharmacological, and molecular modeling studies. J. Med. Chem. 2006, 49, 6015–6026.
  90. Colotta, V.; Lenzi, O.; Catarzi, D.; Varano, F.; Squarcialupi, L.; Costagli, C.; Galli, A.; Ghelardini, C.; Pugliese, A.M.; Maraula, G.; et al. 3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: Molecular modeling and pharmacological studies. Eur. J. Med. Chem. 2012, 54, 470–482.
  91. Lerma, J.; Paternain, A.V.; Rodríguez-Moreno, A.; López-García, J.C. Molecular physiology of kainate receptors. Physiol. Rev. 2001, 81, 971–998.
  92. Wilding, T.J.; Huettner, J.E. Activation and desensitization of hippocampal kainate receptors. J. Neurosci. 1997, 17, 2713–2721.
  93. Shvarts, V.; Chung, S. Perampanel: Newly approved, novel antiepileptic medication for partial-onset seizures. Expert Rev. Neurother. 2013, 13, 131–134.
  94. Fukushima, K.; Hatanaka, K.; Sagane, K.; Ido, K. Inhibitory effect of anti-seizure medications on ionotropic glutamate receptors: Special focus on AMPA receptor subunits. Epilepsy Res. 2020, 167, 106452.
  95. Taniguchi, S.; Stolz, J.R.; Swanson, G.T. The antiseizure drug Perampanel is a subunit-selective negative allosteric modulator of kainate receptors. J. Neurosci. 2022, 42, 5499–5509.
  96. Kanemura, H.; Sano, F.; Aihara, M. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy. Eur. J. Paediatr. Neurol. 2019, 23, 197–203.
  97. Trigg, A.; Brohan, E.; Cocks, K.; Jones, A.; Tahami Monfared, A.A.; Chabot, I.; Meier, G.; Campbell, R.; Li, H.; Ngo, L.Y. Health-related quality of life in pediatric patients with partial onset seizures or primary generalized tonic-clonic seizures receiving adjunctive perampanel. Epilepsy Behav. 2021, 118, 107938.
  98. Mehndiratta, M.M.; Manoj, G.; Jabeen, S.A.; Patten, A. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India. Epilepsia Open 2021, 8, 90–101.
  99. Fogarasi, A.; Flamini, R.; Milh, M.; Phillips, S.; Yoshitomi, S.; Patten, A.; Takase, T.; Laurenza, A.; Ngo, L.Y. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients. Epilepsia 2020, 61, 125–137.
  100. Nishida, T.; Lee, S.K.; Wu, T.; Tiamkao, S.; Dash, A. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations. Epilepsia 2019, 60, 47–59.
  101. Renfroe, J.B.; Mintz, M.; Davis, R.; Ferreira, J.; Dispoto, S.; Ferry, J.; Umetsu, Y.; Rege, B.; Majid, O.; Hussein, Z.; et al. Adjunctive Perampanel oral suspension in pediatric patients from 2 to <12 years of age with epilepsy: Pharmacokinetics, safety, tolerability, and efficacy. J. Child Neurol. 2019, 34, 284–294.
  102. Usui, N.; Akamatsu, N.; Nakasato, N.; Ohnishi, A.; Kaneko, S.; Hiramatsu, H.; Saeki, K.; Miyagishi, H.; Inoue, Y. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy. Seizure 2018, 62, 26–32.
  103. Lin, K.L.; Lin, J.J.; Chou, M.L.; Hung, P.C.; Hsieh, M.Y.; Chou, I.J.; Lim, S.N.; Wu, T.; Wang, H.S. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics. Epilepsy Behav. 2018, 85, 188–194.
  104. Piña-Garza, J.E.; Lagae, L.; Villanueva, V.; Renfroe, J.B.; Laurenza, A.; Williams, B.; Kumar, D.; Meador, K.J. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy Behav. 2018, 83, 50–58.
  105. Eggert, K.; Squillacote, D.; Barone, P.; Dodel, R.; Katzenschlager, R.; Emre, M.; Lees, A.J.; Rascol, O.; Poewe, W.; Tolosa, E.; et al. Safety and efficacy of perampanel in advanced parkinson’s disease: A randomized, placebo-controlled study. Mov. Disord. 2010, 25, 896–905.
  106. Rascol, O.; Barone, P.; Behari, M.; Emre, M.; Giladi, N.; Olanow, C.W.; Ruzicka, E.; Bibbiani, F.; Squillacote, D.; Patten, A.; et al. Perampanel in Parkinson disease fluctuations: A double-blind randomized trial with placebo and entacapone. Clin. Neuropharmacol. 2012, 35, 15–20.
  107. Oskarsson, B.; Mauricio, E.A.; Shah, J.S.; Li, Z.; Rogawski, M.A. Cortical excitability threshold can be increased by the AMPA blocker Perampanel in amyotrophic lateral sclerosis. Muscle Nerve 2021, 64, 215–219.
  108. Aizawa, H.; Kato, H.; Oba, K.; Kawahara, T.; Okubo, Y.; Saito, T.; Naito, M.; Urushitani, M.; Tamaoka, A.; Nakamagoe, K.; et al. Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J. Neurol. 2022, 269, 885–896.
  109. Wilding, T.J.; Chai, Y.H.; Huettner, J.E. Inhibition of rat neuronal kainate receptors by cis-unsaturated fatty acids. J. Physiol. 1998, 513 Pt 2, 331–339.
  110. Wilding, T.J.; Zhou, Y.; Huettner, J.E. Q/R site editing controls kainate receptor inhibition by membrane fatty acids. J. Neurosci. 2005, 25, 9470–9478.
  111. Wilding, T.J.; Fulling, E.; Zhou, Y.; Huettner, J.E. Amino acid substitutions in the pore helix of GluR6 control inhibition by membrane fatty acids. J. Gen. Physiol. 2008, 132, 85–99.
  112. Christensen, J.K.; Paternain, A.V.; Selak, S.; Ahring, P.K.; Lerma, J. A mosaic of functional kainate receptors in hippocampal interneurons. J. Neurosci. 2004, 24, 8986–8993.
  113. Xu, J.; Liu, Y.; Zhang, G.Y. Neuroprotection of GluR5-containing kainate receptor activation against ischemic brain injury through decreasing tyrosine phosphorylation of N-methyl-D-aspartate receptors mediated by Src kinase. J. Biol. Chem. 2008, 283, 29355–29366.
  114. Christensen, J.K.; Varming, T.; Ahring, P.K.; Jørgensen, T.D.; Nielsen, E. In vitro characterization of 5-carboxyl-2,4-di-benzamidobenzoic acid (NS3763), a noncompetitive antagonist of GLUK5 receptors. J. Pharmacol. Exp. Ther. 2004, 309, 1003–1010.
  115. Valgeirsson, J.; Nielsen, E.; Peters, D.; Varming, T.; Mathiesen, C.; Kristensen, A.S.; Madsen, U. 2-arylureidobenzoic acids: Selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. J. Med. Chem. 2003, 46, 5834–5843.
  116. Valgeirsson, J.; Nielsen, E.; Peters, D.; Mathiesen, C.; Kristensen, A.S.; Madsen, U. Bioisosteric modifications of 2-arylureidobenzoic acids: Selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. J. Med. Chem. 2004, 47, 6948–6957.
  117. Anna Kaczor, A.; Kronbach, C.; Unverferth, K.; Pihlaja, K.; Wiinamaki, K.; Sinkkonen, J.; Kijkowska-Murak, U.; Wrobel, T.; Stachal, T.; Matosiuk, D. Novel non-competitive antagonists of kainate GluK1/GluK2 receptors. Lett. Drug Des. Discov. 2012, 9, 891–898.
  118. Kaczor, A.A.; Karczmarzyk, Z.; Fruziński, A.; Pihlaja, K.; Sinkkonen, J.; Wiinämaki, K.; Kronbach, C.; Unverferth, K.; Poso, A.; Matosiuk, D. Structural studies, homology modeling and molecular docking of novel non-competitive antagonists of GluK1/GluK2 receptors. Bioorg. Med. Chem. 2014, 22, 787–795.
  119. Bartyzel, A.; Kaczor, A.A.; Mahmoudi, G.; Masoudiasl, A.; Wróbel, T.M.; Pitucha, M.; Matosiuk, D. Experimental and computational structural studies of 2,3,5-trisubstituted and 1,2,3,5-tetrasubstituted indoles as non-competitive antagonists of GluK1/GluK2 receptors. Molecules 2022, 27, 2479.
  120. Ben-Menachem, E. Topiramate: Current status and therapeutic potential. Expert Opin. Investig. Drugs 1997, 6, 1085–1094.
  121. Kaminski, R.M.; Banerjee, M.; Rogawski, M.A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004, 46, 1097–1104.
  122. Braga, M.F.M.; Aroniadou-Anderjaska, V.; Li, H.; Rogawski, M.A. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABA_A receptors on principal neurons. J. Pharmacol. Exp. Ther. 2009, 330, 558–566.
  123. Gryder, D.S.; Rogawski, M.A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci. 2003, 23, 7069–7074.
  124. Available online: www.clinicaltrials.gov (accessed on 8 December 2022).
  125. Strømgaard, K.; Andersen, K.; Krogsgaard-Larsen, P.; Jaroszewski, J.W. Recent advances in the medicinal chemistry of polyamine toxins. Mini-Rev. Med. Chem. 2001, 1, 317–338.
  126. Brown, P.M.; Aurousseau, M.R.; Musgaard, M.; Biggin, P.C.; Bowie, D. Kainate receptor pore-forming and auxiliary subunits regulate channel block by a novel mechanism. J. Physiol. 2016, 594, 1821–1840.
  127. Perrais, D.; Coussen, F.; Mulle, C. Atypical functional properties of GluK3-containing kainate receptors. J. Neurosci. 2009, 29, 15499–15510.
  128. Lomeli, H.; Wisden, W.; Köhler, M.; Keinänen, K.; Sommer, B.; Seeburg, P.H. High-affinity kainate and domoate receptors in rat brain. FEBS Lett. 1992, 307, 139–143.
  129. Hansen, K.B.; Wollmuth, L.P.; Bowie, D.; Furukawa, H.; Menniti, F.S.; Sobolevsky, A.I.; Swanson, G.T.; Swanger, S.A.; Greger, I.H.; Nakagawa, T.; et al. Structure, function, and pharmacology of glutamate receptor ion channels. Pharmacol. Rev. 2021, 73, 298–487.
  130. Bowie, D. Polyamine-mediated channel block of ionotropic glutamate receptors and its regulation by auxiliary proteins. J. Biol. Chem. 2018, 293, 18789–18802.
  131. Mott, D.D.; Washburn, M.S.; Zhang, S.; Dingledine, R.J. Subunit-dependent modulation of kainate receptors by extracellular protons and polyamines. J. Neurosci. 2003, 23, 1179–1188.
  132. Quistad, G.B.; Suwanrumpha, S.; Jarema, M.A.; Shapiro, M.J.; Skinner, W.S.; Jamieson, G.C.; Lui, A.; Fu, E.W. Structure of paralytic acylpolyamines from the spider Agelenopsisaperta. Biochem. Biophys. Res. Commun. 1990, 169, 51–56.
  133. Eldefrawi, A.T.; Eldefrawi, M.E.; Konnot, K.; Mansour, N.A.; Nakanishit, K.; Oltzt, E.; Usherwood, P.N.R. Structure and synthesis of a potent glutamate receptor antagonist in wasp venom (wasp venom toxin/quisqualate receptor). Proc. Natl. Acad. Sci. USA 1988, 85, 4910–4913.
  134. Kachel, H.S.; Franzyk, H.; Mellor, I.R. Philanthotoxin analogues that selectively inhibit ganglionic nicotinic acetylcholine receptors with exceptional potency. J. Med. Chem. 2019, 62, 6214–6222.
  135. Vassileiou, C.; Kalantzi, S.; Vachlioti, E.; Athanassopoulos, C.M.; Koutsakis, C.; Piperigkou, Z.; Karamanos, N.; Stivarou, T.; Lymberi, P.; Avgoustakis, K.; et al. New analogs of polyamine toxins from spiders and wasps: Liquid phase fragment synthesis and evaluation of antiproliferative activity. Molecules 2022, 27, 447.
  136. Verdoni, M.; Roudaut, H.; De Pomyers, H.; Gigmes, D.; Bertin, D.; Luis, J.; Bengeloune, A.H.; Mabrouk, K. ArgTX-636, a polyamine isolated from spider venom: A novel class of melanogenesis inhibitors. Bioorg. Med. Chem. 2016, 24, 5685–5692.
  137. Kromann, H.; Krikstolaityte, S.; Andersen, A.J.; Andersen, K.; Krogsgaard-Larsen, P.; Jaroszewski, J.W.; Egebjerg, J.; Strømgaard, K. Solid-phase synthesis of polyamine toxin analogues: Potent and selective antagonists of Ca2+-permeable AMPA receptors. J. Med. Chem. 2002, 45, 5745–5754.
  138. Kachel, H.S.; Patel, R.N.; Franzyk, H.; Mellor, I.R. Block of nicotinic acetylcholine receptors by philanthotoxins is strongly dependent on their subunit composition. Sci. Rep. 2016, 6, 38116.
  139. Matavel, A.; Estrada, G.; De Marco Almeida, F. Spider venom and drug discovery: A review. In Spider Venoms; Springer: Dordrecht, The Netherlands, 2016; pp. 273–292.
  140. Magazanik, L.G.; Buldakova, S.L.; Samoilova, M.V.; Gmiro, V.E.; Mellor, I.R.; Usherwood, P.N.R. Block of open channels of recombinant AMPA receptors and native AMPA/kainate receptors by adamantane derivatives. J. Physiol. 1997, 505 Pt 3, 655–663.
  141. Koike, M.; Iino, M.; Ozawa, S. Blocking effect of 1-naphthyl acetyl spermine on Ca2+-permeable AMPA receptors in cultured rat hippocampal neurons. Neurosci. Res. 1997, 29, 27–36.
  142. Nelson, J.K.; Frølund, S.U.; Tikhonov, D.B.; Kristensen, A.S.; Strømgaard, K. Synthesis and biological activity of argiotoxin 636 and analogues: Selective antagonists for ionotropic glutamate receptors. Angew. Chem. Int. Ed. 2009, 48, 3087–3091.
  143. Xiong, X.F.; Poulsen, M.H.; Hussein, R.A.; Nørager, N.G.; Strømgaard, K. Structure-activity relationship study of spider polyamine toxins as inhibitors of ionotropic glutamate receptors. ChemMedChem 2014, 9, 2661–2670.
  144. Nørager, N.G.; Poulsen, M.H.; Jensen, A.G.; Jeppesen, N.S.; Kristensen, A.S.; Strømgaard, K. Structure−activity relationship studies of n-methylated and n-hydroxylated spider polyamine toxins as inhibitors of ionotropic glutamate receptors. J. Med. Chem. 2014, 57, 4940–4949.
  145. Poulsen, M.H.; Lucas, S.; Bach, T.B.; Barslund, A.F.; Wenzler, C.; Jensen, C.B.; Kristensen, A.S.; Strømgaard, K. Structure−Activity relationship studies of argiotoxins: Selective and potent inhibitors of ionotropic glutamate receptors. J. Med. Chem. 2013, 56, 1171–1181.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback